SATURDAY, JUNE 23, 2018

LabCorp shares 2 new hepatitis C virus drug resistance assays

Courtesy of hepatitiscnewdrugresearch.com
Laboratory Corporation of America Holdings (LabCorp) recently launched two new hepatitis C virus (HCV) drug resistance assays.

The HCV NS5A and NS5B Drug Resistance Assays join HCV GenoSure NS3/4A in LabCorp's arsenal of HCV resistance tests. They are available to the public via Monogram Biosciences, which is a branch of the LabCorp Specialty Testing Group.

Chronic HCV is the main cause of liver failure and hepatocellular carcinoma. The U.S. Centers for Disease Control and Prevention estimates that more than 3 million people  in the U.S. and 170 million people worldwide live with HCV infections.

Since 2011, the U.S. Food and Drug Administration (FDA) has approved six new HCV treatment applications. All involve one or more direct acting antiviral (DAA) agents, because these agents drastically improve HCV rates when compared with interferon-based treatments.

“LabCorp’s launch of the HCV NS5A and NS5B Drug Resistance Assays, combined with the first-to-market HCV GenoSure NS3/4A Assay, enables clinicians to assess resistance to all of the DAA treatment regimens that have been approved by the FDA,” Dr. Marcia Eisenberg, LabCorp Diagnostics’ chief scientific officer, said. “LabCorp’s expanded HCV drug resistance testing portfolio is the latest example of LabCorp’s commitment to deliver world-class diagnostics to reduce treatment failures and improve patient outcomes at lower costs.”

Organizations in this Story

Labcorp of America U.S. Food and Drug Administration (FDA)

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.